Portfolio & Pipeline

Other than Apta-1, the company has two more therapeutic candidates in its pipeline – Apta-2 and Apta-3, which currently are in early preclinical phase and discovery phase, respectively. Apta-2 has in initial studies showed promising properties while Apta-3 needs further evaluation.

In addition to internal development of their pharmaceutical candidates, Aptahem continuously evaluates potential expansion possibilities of its portfolio. The company currently evaluates possible partnerships with relevant players in the industry for their lead candidate, Apta-1. In addition, the company evaluates the possibilities of procuring new candidates via in-licensing or acquisition to expand the development portfolio.

Aptahem welcomes collaborations with academic groups around the world where their RNA-based therpeutical candidates can be studied in conditions including coagulation, inflammation or immunomodulation.